Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 731-739, February 1, 2008. doi: 10.1158/0008-5472.CAN-07-2668
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Tahir, S. A.
Right arrow Articles by Thompson, T. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahir, S. A.
Right arrow Articles by Thompson, T. C.

Cell, Tumor, and Stem Cell Biology

Tumor Cell–Secreted Caveolin-1 Has Proangiogenic Activities in Prostate Cancer

Salahaldin A. Tahir1, Guang Yang1, Alexei A. Goltsov1, Masami Watanabe1, Ken-ichi Tabata1, Josephine Addai1, El Moataz Abdel Fattah1, Dov Kadmon1 and Timothy C. Thompson1,2,3

1 Scott Department of Urology, Departments of 2 Molecular and Cellular Biology and 3 Radiology, Baylor College of Medicine, Houston, Texas

Requests for reprints: Timothy C. Thompson, The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Unit 1374, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-9955; Fax: 713-792-9956; E-mail: timthomp{at}mdanderson.org.

Key Words: caveolin-1 • uptake • angiogenesis • prostate cancer • endothelial cells

Caveolin, a major structural component of specialized plasma membrane invaginations (caveolae) that participate in diverse cellular activities, has been implicated in the pathogenesis of several human diseases, including cancer. We showed in earlier studies that caveolin-1 (cav-1) is consistently and strongly overexpressed in metastatic prostate cancer and is secreted in a biologically active form by virulent prostate cancer cells. Using both in vitro and in vivo model systems, we now present evidence supporting a proangiogenic role for cav-1 in prostate cancer development and progression. Recombinant cav-1 (rcav-1) was taken up by cav-1–/– endothelial cells through either a lipid raft/caveolae- or clathrin-dependent mechanism, leading to specific angiogenic activities (tubule formation, cell migration, and nitric oxide production) that were mediated by rcav-1 stimulation of the PI3K-Akt-eNOS signaling module. Pathologic angiogenesis induced by cav-1 in prostate cancer–bearing mice correlated with an increased frequency, number, and size of lung metastases. We propose that in addition to its antiapoptotic role, cav-1 secreted by prostate cancer cells functions critically as a proangiogenic factor in metastatic progression of this tumor. These new insights into cav-1 function in prostate cancer may provide a base for the design of clinically applicable therapeutic strategies. [Cancer Res 2008;68(3):731–9]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.